Cristiano Ferrario

Montreal, QC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 51 publications

Outcomes of a Canadian real-world cohort of metastatic castration-sensitive prostate cancer patients stratified by early PSA nadir.

Outcomes of a Canadian real-world cohort of metastatic castration-sensitive prostate cancer patients stratified by early PSA nadir.

Journal: Future oncology (London, England)

Published: June 19, 2026

Genetic testing practices among specialist physicians who treat prostate cancer: Updated survey of Canadian practitioners.

Genetic testing practices among specialist physicians who treat prostate cancer: Updated survey of Canadian practitioners.

Journal: Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Published: April 06, 2026

Genetic testing practices among specialist physicians who treat prostate cancer Updated survey of Canadian practitioners.

Genetic testing practices among specialist physicians who treat prostate cancer Updated survey of Canadian practitioners.

Journal: Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Published: April 06, 2026

Correction to: A Canadian real‑world, multi‑center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2‑negative advanced breast cancer.

Correction to: A Canadian real‑world, multi‑center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2‑negative advanced breast cancer.

Journal: Breast cancer research and treatment

Published: March 19, 2026

Evaluating the Role of Liquid Biopsy to Detect Pathogenic Homologous Recombination Repair (HRR) Gene Alterations in Metastatic Prostate Cancer.

Evaluating the Role of Liquid Biopsy to Detect Pathogenic Homologous Recombination Repair (HRR) Gene Alterations in Metastatic Prostate Cancer.

Journal: Cancers

Published: August 17, 2025

Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancer.

Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancer.

Journal: Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Published: October 29, 2024

The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre.

The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre.

Journal: Current oncology (Toronto, Ont.)

Published: October 15, 2024

High Ki-67 expression is associated with increased risk of distant recurrence in Oncotype Dx low risk breast cancer.

High Ki-67 expression is associated with increased risk of distant recurrence in Oncotype Dx low risk breast cancer.

Journal: Clinical breast cancer

Published: October 08, 2024

A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2-negative advanced breast cancer.

A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2-negative advanced breast cancer.

Journal: Breast cancer research and treatment

Published: June 28, 2024

Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial.

Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial.

Journal: Nature medicine

Published: June 24, 2024

A phase 2, single-arm trial evaluating 131 I-PSMA-1095 targeted radioligand therapy for metastatic castration-resistant prostate cancer.

A phase 2, single-arm trial evaluating 131 I-PSMA-1095 targeted radioligand therapy for metastatic castration-resistant prostate cancer.

Journal: Nuclear medicine communications

Published: May 10, 2024

Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinoma: a multicentre retrospective cohort study.

Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinoma: a multicentre retrospective cohort study.

Journal: BMJ open

Published: March 29, 2024

Showing 1-12 of 51

Last Updated: 09/26/2026